CAS 17360-35-9|Oxotremorine sesquifumarate
Introduction：Basic information about CAS 17360-35-9|Oxotremorine sesquifumarate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Oxotremorine sesquifumarate | ||
|---|---|---|---|
| CAS Number | 17360-35-9 | Molecular Weight | 760.78500 |
| Density | / | Boiling Point | 373.9ºC at 760 mmHg |
| Molecular Formula | C36H48N4O14 | Melting Point | 102-105ºC(lit.) |
| MSDS | ChineseUSA | Flash Point | 169.1ºC |
| Symbol | GHS06 | Signal Word | Danger |
Names
| Name | Oxotremorine sesquifumarate salt |
|---|---|
| Synonym | More Synonyms |
Oxotremorine sesquifumarate BiologicalActivity
| Description | Oxotremorine sesquifumarate is a mAChR agonist that mainly activates M2 receptors. Oxotremorine sesquifumarate can be used for neurological research[1][2]. |
|---|---|
| Related Catalog | Signaling Pathways >>Neuronal Signaling >>mAChRSignaling Pathways >>GPCR/G Protein >>mAChRResearch Areas >>Neurological Disease |
| In Vitro | Oxotremorine (10.5 μM) produces a paralytic effect on twitch responses of rat diaphragm in vitro to direct and indirect stimulation[1]. |
| In Vivo | In rats with sciatic nerve injuries, Oxotremorine (10, 5, 2 1 μg; 10 μL) i.t. dose-dependently suppresses the tactile hypersensitivity[2]. |
| References | [1]. M Das, D K Ganguly, et al. Enhancement by oxotremorine of acetylcholine release from the rat phrenic nerve. Br J Pharmacol. 1978 Feb;62(2):195-8. [2]. Zhiyang Song, et al. Muscarinic receptor activation potentiates the effect of spinal cord stimulation on pain-related behavior in rats with mononeuropathy. Neurosci Lett. 2008 May 2;436(1):7-12. |
Chemical & Physical Properties
| Boiling Point | 373.9ºC at 760 mmHg |
|---|---|
| Melting Point | 102-105ºC(lit.) |
| Molecular Formula | C36H48N4O14 |
| Molecular Weight | 760.78500 |
| Flash Point | 169.1ºC |
| Exact Mass | 760.31700 |
| PSA | 270.90000 |
| LogP | 0.30300 |
| Vapour Pressure | 8.7E-06mmHg at 25°C |
| InChIKey | WLYYOFJEBGHKEC-VQYXCCSOSA-N |
| SMILES | O=C(O)C=CC(=O)O.O=C(O)C=CC(=O)O.O=C(O)C=CC(=O)O.O=C1CCCN1CC#CCN1CCCC1.O=C1CCCN1CC#CCN1CCCC1 |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 6500 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 28,227,1974
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 20 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- CSLNX* U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. (Aberdeen Proving Ground, MD 21010) Volume(issue)/page/year: NX#04243 ** OTHER MULTIPLE DOSE TOXICITY DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 21 mg/kg/7D-I
- TOXIC EFFECTS :
- Brain and Coverings - other degenerative changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - true cholinesterase Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other esterases
- REFERENCE :
- DTESD7 52 Vanderbilt Ave., New York, NY 10017) V.1-15, 1977-87. Discontinued 52 Vanderbilt Ave., New York, NY 10017) V.1- 1977- Volume(issue)/page/year: 11,495,1983
Safety Information
| Symbol | GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H300-H310-H330 |
| Precautionary Statements | P260-P264-P280-P284-P302 + P350-P310 |
| Personal Protective Equipment | Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | T+ |
| Risk Phrases | 26/27/28 |
| Safety Phrases | S28;S45;S36/S37 |
| RIDADR | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS | UY6000000 |
| Packaging Group | I |
| Hazard Class | 6.1(a) |
Articles12
More Articles| Acetylcholine activity in selective striatal regions supports behavioral flexibility. Neurobiol. Learn. Mem. 91(1) , 13-22, (2009) Daily living often requires individuals to flexibly respond to new circumstances. There is considerable evidence that the striatum is part of a larger neural network that supports flexible adaptations... | |
| Stress-induced immobility in rats with cholinergic supersensitivity. Biol. Psychiatry 21(7) , 657-64, (1986) Immobility during forced swimming or after mild footshock (1 mA for 2 sec) was observed in five groups of rats. The Flinders Sensitive Line (FSL) of rats, known to be more sensitive to cholinergic ago... | |
| Memory-modulatory effects of centrally acting noradrenergic drugs: possible involvement of brain cholinergic mechanisms. Behav. Neural Biol 57(3) , 248-55, (1992) Post-training administration of the centrally acting muscarinic agonist oxotremorine (50.0 microgram/kg, ip) facilitated 48-hr retention, in mice, of a one-trial step-through inhibitory avoidance resp... |
Synonyms
| EINECS 241-388-3 |
| MFCD00013163 |
| 1-(4-[1-Pyrrolidinyl]-2-butynyl)-2-pyrrolidinone 1-(4-[1-Pyrrolidinyl]2-butynyl)-2-pyrrolidinone |
| Oxotremorine sesquifumarate,1-[4-(1-Pyrrolidinyl)-2-butynyl]-2-pyrrolidinonesesquifumarate |
